Voyager Therapeutics Inc VYGR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 60.42M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.11
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 141
Valuation
|
Metric
|
VYGR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.31 |
Price/Sales | 6.11 |
Price/Cash Flow | — |
Price/Earnings
VYGR
Financial Strength
|
Metric
|
VYGR
|
|---|---|
Quick Ratio | 8.20 |
Current Ratio | 8.42 |
Interest Coverage | — |
Quick Ratio
VYGR
Profitability
|
Metric
|
VYGR
|
|---|---|
Return on Assets (Normalized) | −36.86% |
Return on Equity (Normalized) | −47.82% |
Return on Invested Capital (Normalized) | −46.38% |
Return on Assets
VYGR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n$CFy! | LOCK|qg># | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$tcGHJJ | LOCK|cD@f< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|wD?!ZkY | LOCK|^> | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|WwR&^? | LOCK|^@?$ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v?zqRwq | LOCK|P! | $36B | |||
| Moderna Inc
MRNA
| LOCK|$d>^#^ | LOCK|LC^ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|g!vF!w<< | LOCK|sHS?N | $25B | |||
| Incyte Corp
INCY
| LOCK|y%^sb^ | LOCK|#WB | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$F@C&<S | LOCK|d% | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&cm>#Rn | LOCK|%q! | $17B |
United States